Generated by AI
PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types. PMV Pharmaceuticals concentrates on translational research and clinical development for advanced solid tumors, combining drug discovery with mutation-specific biology to create targeted treatment options. Based in Princeton, New Jersey, the company operates within the broader cancer therapeutics market and is recognized for its work in mutant p53 biology and small-molecule precision medicine.
Website400 Alexander Park Drive
Princeton, NJ, 08540
United States
The latest articles about PMVP.
Summary of Sep 1's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appoint
Summary of Sep 1's posts. Generated by AI.
Investors talking about PMVP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.